Atlas Trials

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens

Clinical trial NCT01406938 · COMPLETED

Trial details

NCT number
NCT01406938
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Moderate to Severe Plaque-type Psoriasis
Start date
2011-08-01
Primary completion
2013-05-01
Enrollment
967

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.